Developing therapeutic immunoglobulins: European regulatory perspectives and implications.
Prepared from pooled human blood/plasma, therapeutic immunoglobulins contain the natural antibody spectrum of the entire donor population and mediate a range of therapeutic effects when administered to patients. They are particularly indicated for the prevention of serious and life-threatening infections in patients with immune systems failing to produce functional antibodies. Other than treatment of such rare primary immunodeficiencies (primary antibody deficiencies), therapeutic immunoglobulins are also used in certain inflammatory and autoimmune disorders, including immune thrombocytopenic purpura, Guillain Barré syndrome, and Kawasaki disease. The conditions for licensure of therapeutic immunoglobulins in the EU and the associated regulatory issues and procedures are reviewed. Regulatory expectations about the manufacture and control of immunoglobulins are highlighted and safety and efficacy requirements described. Although the main focus is on European pharmaceutical legislation, other applicable public information is considered.
Kurz
Manfred
M
Regulatory Affairs, CSL Behring AG, Bern, Switzerland. kurz@lycos.com
D000818:Animals; D001800:Blood Specimen Collection; D004335:Drug and Narcotic Control; D005060:Europe; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007136:Immunoglobulins / Q000009:adverse effects / Q000627:therapeutic use*; D011786:Quality Control
D007074:Immunoglobulin G; D007136:Immunoglobulins